Details of the Drug

General Information of Drug (ID: DM8LBYT)

Drug Name
NIS793
Indication
Disease Entry ICD 11 Status REF
Pancreatic ductal carcinoma 2C10.0 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Cross-matching ID
TTD ID
D07VHU
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transforming growth factor beta (TGFB) TTO3HT7 NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04390763) Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)